CN Patent

CN1805749A — 星孢素衍生物的新药物用途

Assigned to Novartis AG · Expires 2006-07-19 · 20y expired

What this patent protects

本申请涉及星孢素衍生物在治愈、缓和或预防性治疗变应性鼻炎、变应性皮炎、药物变态反应或食物变态反应、血管神经性水肿、荨麻疹、婴儿猝死综合征、支气管肺曲霉病、多发性硬化症或肥大细胞病中的用途；还涉及治疗恒温动物的方法，其中给患有上文提到的疾病或病症之一的恒温动物施用治疗有效剂量的星孢素衍生物化合物。

USPTO Abstract

本申请涉及星孢素衍生物在治愈、缓和或预防性治疗变应性鼻炎、变应性皮炎、药物变态反应或食物变态反应、血管神经性水肿、荨麻疹、婴儿猝死综合征、支气管肺曲霉病、多发性硬化症或肥大细胞病中的用途；还涉及治疗恒温动物的方法，其中给患有上文提到的疾病或病症之一的恒温动物施用治疗有效剂量的星孢素衍生物化合物。

Drugs covered by this patent

Rydapt (MIDOSTAURIN) · Novartis

Patent Metadata

Patent number: CN1805749A
Jurisdiction: CN
Classification: —
Expires: 2006-07-19
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.